SCHEMBL281838

SCHEMBL281838

COC(=O)c1cccc(CN2C(=O)C(=O)c3ccccc32)c1

nearest known ligand 0.71

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TRPA1 O75762 1/20 0.71
ALDH1A1 P00352 4/20 0.58
CES1 P23141 4/20 0.58
ALDH3A1 P30838 2/20 0.58
CHRM1 P11229 2/20 0.58
ALDH2 P05091 1/20 0.58
HPGD P15428 1/20 0.58
HTT P42858 1/20 0.58
IDO1 P14902 1/20 0.55
GSK3B P49841 1/20 0.53
TP53 P04637 2/20 0.53
ACHE P22303 2/20 0.53
HSD17B10 Q99714 2/20 0.53
MAPT P10636 2/20 0.53
BCHE P06276 2/20 0.53
APAF1 O14727 1/20 0.53
CYP1A2 P05177 1/20 0.53
CYP3A4 P08684 1/20 0.53
CYP2D6 P10635 1/20 0.53
ALOX15 P16050 1/20 0.53

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL28799626 0.86 ALDH1A1 (0.62) TRPA1ALDH1A1CES1ALDH3A1CHRM1
SCHEMBL28946310 0.86 ALDH3A1 (0.64) TRPA1ALDH1A1ALDH3A1ALDH2TP53
SCHEMBL1445504 0.86 PRKAG1 (0.69) TRPA1IDO1GSK3BTP53MAPT
SCHEMBL281270 0.86 CES1 (0.63) TRPA1ALDH1A1CES1ALDH3A1CHRM1
SCHEMBL1164954 0.86 KMT2A (0.70) TRPA1IDO1GSK3BTP53HSD17B10
SCHEMBL31753576 0.86 KMT2A (0.70) TRPA1IDO1GSK3BTP53HSD17B10
SCHEMBL18954771 0.85 KMT2A (0.72) ALDH1A1CES1ALDH3A1CHRM1ALDH2
SCHEMBL1061275 0.84 TRPA1 (0.83) TRPA1GSK3BTP53MAPTKMT2A
SCHEMBL1061274 0.84 TRPA1 (0.83) TRPA1GSK3BTP53MAPTKMT2A
SCHEMBL29699673 0.84 CES1 (0.59) TRPA1ALDH1A1CES1ALDH3A1CHRM1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 34 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-111747883-B 1-benzyl isatin derivative and synthesis method and application thereof 中南大学 2022-07-01 CN disclosed
CN-111747883-A 1-benzyl isatin derivative and synthesis method and application thereof 中南大学 2020-10-09 CN disclosed
EP-3241834-A1 SPIRO-OXINDOLE COMPOUNDS AND THEIR USES AS THERAPEUTIC AGENTS Xenon Pharmaceuticals Inc. (CA) 2017-11-08 EP disclosed
EP-2428515-B9 Spiro-oxindole compounds and their uses as therapeutic agents XENON PHARMACEUTICALS INC (CA) 2014-09-17 EP disclosed
EP-2752417-A1 Spiro-oxindole compounds and their uses as therapeutic agents Xenon Pharmaceuticals Inc. (CA) 2014-07-09 EP disclosed
EP-2428515-B1 Spiro-oxindole compounds and their uses as therapeutic agents XENON PHARMACEUTICALS INC (CA) 2014-05-07 EP disclosed
US-8466188-B2 Use of spiro-oxindole compounds as therapeutic agents XENON PHARMACEUTICALS INC. (CA) 2013-06-18 US disclosed
US-20120122909-A9 SPIRO-OXINDOLE COMPOUNDS AND THEIR USES AS THERAPEUTIC AGENTS XENON PHARMACEUTICALS INC. (CA) 2012-05-17 US disclosed
EP-2428515-A1 Spiro-oxindole compounds and their uses as therapeutic agents Xenon Pharmaceuticals Inc. (CA) 2012-03-14 EP disclosed
EP-2073806-B1 USE OF SPIRO-OXINDOLE COMPOUNDS AS THERAPEUTIC AGENTS XENON PHARMACEUTICALS INC (CA) 2012-02-15 EP disclosed
CN-101213174-A Oxindole compounds and their uses as therapeutic agents XENON PHARMACEUTICALS INC (CA) 2008-07-02 CN disclosed
WO-2008060789-A2 USE OF SPIRO-OXINDOLE COMPOUNDS AS THERAPEUTIC AGENTS XENON PHARMACEUTICALS INC. (CA) 2008-05-22 WO disclosed
CN-101184761-A Spiro-indolone compounds and their use as therapeutic agents XENON PHARMACEUTICALS INC (CA) 2008-05-21 CN disclosed
WO-2008046083-A2 USE OF OXINDOLE COMPOUNDS AS THERAPEUTIC AGENTS XENON PHARMACEUTICALS INC. (CA) 2008-04-17 WO disclosed
EP-1888595-A2 SPIRO-OXINDOLE COMPOUNDS AND THEIR USES AS THERAPEUTIC AGENTS XENON PHARMACEUTICALS INC. (CA) 2008-02-20 EP disclosed
EP-1877378-A2 OXINDOLE COMPOUNDS AND THEIR USES AS THERAPEUTIC AGENTS XENON PHARMACEUTICALS INC. (CA) 2008-01-16 EP disclosed
US-20070105820-A1 Oxindole compounds and their uses as therapeutic agents XENON PHARMACEUTICALS INC. (CA) 2007-05-10 US disclosed
US-20060252812-A1 Spiro-oxindole compounds and their uses as therapeutic agents XENON PHARMACEUTICALS INC. (CA) 2006-11-09 US disclosed
WO-2006113864-A2 OXINDOLE COMPOUNDS AND THEIR USES AS THERAPEUTIC AGENTS XENON PHARMACEUTICALS INC. (CA) 2006-10-26 WO disclosed
WO-2006110917-A2 SPIRO-OXINDOLE COMPOUNDS AND THEIR USES AS THERAPEUTIC AGENTS XENON PHARMACEUTICALS INC. (CA) 2006-10-19 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070105820-A1 Oxindole compounds and their uses as therapeutic agents OPRL1, OPRK1, TRPV1 TRPA1 15/4885ALDH1A1 1136/4885CES1 4183/4885
US-20120122909-A9 SPIRO-OXINDOLE COMPOUNDS AND THEIR USES AS THERAPEUTIC AGENTS OPRK1, OPRD1, SCN3A TRPA1 57/4885ALDH1A1 838/4885CES1 3669/4885
US-20060252812-A1 Spiro-oxindole compounds and their uses as therapeutic agents OPRK1, OPRD1, SCN3A TRPA1 57/4885ALDH1A1 838/4885CES1 3669/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.